Anusree Majumder1, Rajat Jagani2, Atoshi Basu3. 1. Graded Specialist (Pathology), Command Hospital (Southern Command), Pune 411040, India. 2. Commanding Officer, Armed Forces Transfusion Centre, Delhi 110010, India. 3. Consultant Pathologist, Apollo Hospitals, Kolkata, India.
Abstract
BACKGROUND: Basal-like breast cancer has an unfavorable prognosis. Immunohistochemically, they are predominantly estrogen receptor (ER), progesterone receptor (PR) and CerbB2 receptor (HER2)-negative, show expression of Cytokeratins (CKs) 5/6, CK14, CK 17 and P-cadherin and are associated with germline BRCA1 mutations. Immunohistochemistry (IHC) is an easily available and relatively inexpensive technique that can detect this cancer subtype, and patients can benefit from aggressive management protocols. The aim of this study was to evaluate the expression of CK 5/6 and CK14 in breast cancer and its correlation with age, tumor grade, tumor size, histomorphological pattern, nodal status, ER, PR, HER2/neu, and Ki-67 index. METHODS: Fifty treatment-naїve patients of breast carcinoma who underwent surgery constituted the study group. No core cut biopsy specimens were considered. Histopathological examination along with IHC was performed for CK5/6, CK14, ER, PR, HER2/neu, and Ki-67. Comparison between the expression of CK5/6 and CK14 with age, tumor size, tumor grade, histological subtype, nodal status, ER, PR, HER2/neu, and Ki-67 expression was performed using SPSS 20 version software. RESULTS: Twenty-six percent of cases showed expression of CK5/6 and CK14. CK5/6 and CK14 expression correlated strongly with ER/PR negativity, young age, and Ki-67 proliferative index greater than 15%. No significant association with HER2/neu negativity was demonstrated. Contrasting results were obtained between CK5/6 and CK14 expression with respect to tumor grade and lymph node status. CONCLUSION: IHC can be used to identify patients with basal phenotype breast cancer with good sensitivity and specificity, and such patients can benefit from aggressive management.
BACKGROUND: Basal-like breast cancer has an unfavorable prognosis. Immunohistochemically, they are predominantly estrogen receptor (ER), progesterone receptor (PR) and CerbB2 receptor (HER2)-negative, show expression of Cytokeratins (CKs) 5/6, CK14, CK 17 and P-cadherin and are associated with germline BRCA1 mutations. Immunohistochemistry (IHC) is an easily available and relatively inexpensive technique that can detect this cancer subtype, and patients can benefit from aggressive management protocols. The aim of this study was to evaluate the expression of CK 5/6 and CK14 in breast cancer and its correlation with age, tumor grade, tumor size, histomorphological pattern, nodal status, ER, PR, HER2/neu, and Ki-67 index. METHODS: Fifty treatment-naїve patients of breast carcinoma who underwent surgery constituted the study group. No core cut biopsy specimens were considered. Histopathological examination along with IHC was performed for CK5/6, CK14, ER, PR, HER2/neu, and Ki-67. Comparison between the expression of CK5/6 and CK14 with age, tumor size, tumor grade, histological subtype, nodal status, ER, PR, HER2/neu, and Ki-67 expression was performed using SPSS 20 version software. RESULTS: Twenty-six percent of cases showed expression of CK5/6 and CK14. CK5/6 and CK14 expression correlated strongly with ER/PR negativity, young age, and Ki-67 proliferative index greater than 15%. No significant association with HER2/neu negativity was demonstrated. Contrasting results were obtained between CK5/6 and CK14 expression with respect to tumor grade and lymph node status. CONCLUSION: IHC can be used to identify patients with basal phenotype breast cancer with good sensitivity and specificity, and such patients can benefit from aggressive management.
Authors: Matt van de Rijn; Charles M Perou; Rob Tibshirani; Phillippe Haas; Olli Kallioniemi; Juha Kononen; Joachim Torhorst; Guido Sauter; Markus Zuber; Ossi R Köchli; Frank Mross; Holger Dieterich; Rob Seitz; Doug Ross; David Botstein; Pat Brown Journal: Am J Pathol Date: 2002-12 Impact factor: 4.307
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: Maggie C U Cheang; Miguel Martin; Torsten O Nielsen; Aleix Prat; David Voduc; Alvaro Rodriguez-Lescure; Amparo Ruiz; Stephen Chia; Lois Shepherd; Manuel Ruiz-Borrego; Lourdes Calvo; Emilio Alba; Eva Carrasco; Rosalia Caballero; Dongsheng Tu; Kathleen I Pritchard; Mark N Levine; Vivien H Bramwell; Joel Parker; Philip S Bernard; Matthew J Ellis; Charles M Perou; Angelo Di Leo; Lisa A Carey Journal: Oncologist Date: 2015-04-23
Authors: E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis Journal: J Pathol Date: 2006-03 Impact factor: 7.996
Authors: Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes Journal: J Natl Cancer Inst Date: 2011-09-29 Impact factor: 13.506
Authors: Eric Hahnen; Bianca Lederer; Jan Hauke; Sibylle Loibl; Sandra Kröber; Andreas Schneeweiss; Carsten Denkert; Peter A Fasching; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Sherko Kümmel; Christian Schem; Guido Neidhardt; Jens Huober; Kerstin Rhiem; Serban Costa; Janine Altmüller; Claus Hanusch; Holger Thiele; Volkmar Müller; Peter Nürnberg; Thomas Karn; Valentina Nekljudova; Michael Untch; Gunter von Minckwitz; Rita K Schmutzler Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777